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Objective(s): High variability in clinical response to metformin is often observed in type 2 diabetes (T2D) patients, and 
it highlights the need for identification of genetic components affecting the efficiency of metformin therapy. Aim of 
this observational study is to evaluate the role of tagSNPs (tagging single nucleotide polymorphisms) from genomic 
regions coding for six metformin transporter genes with respect to the short-term efficiency.
Design: 102 tagSNPs in 6 genes coding for metformin transporters were genotyped in the group of 102 T2D patients 
treated with metformin for 3 months.
Methods: Most significant hits were analyzed in the group of 131 T2D patients from Slovakia. Pharmacokinetic study 
in 25 healthy nondiabetic volunteers was conducted to investigate the effects of identified polymorphisms.
Results: In the discovery group of 102 patients, minor alleles of rs3119309, rs7757336 and rs2481030 were significantly 
nominally associated with metformin inefficiency (P = 1.9 × 10−6 to 8.1 × 10−6). Effects of rs2481030 and rs7757336 did 
not replicate in the group of 131 T2DM patients from Slovakia alone, whereas rs7757336 was significantly associated 
with a reduced metformin response in combined group. In pharmacokinetic study, group of individuals harboring risk 
alleles of rs7757336 and rs2481030 displayed significantly reduced AUC∞ of metformin in plasma.
Conclusions: For the first time, we have identified an association between the lack of metformin response and SNPs 
rs3119309 and rs7757336 located in the 5′ flanking region of the genes coding for Organic cation transporter 2 and 
rs2481030 located in the 5′ flanking region of Organic cation transporter 3 that was supported by the results of a 
pharmacokinetic study on 25 healthy volunteers.



























Metformin (1,1-dimethylbiguanide) is prescribed to at 
least 120 million people worldwide to treat hyperglycemia 
(1). It is recommended as the first drug of choice for 
type 2 diabetes (T2D) according to the guidelines of 
the ADA (American Diabetes Association) and EASD 
(European Association for the Study of Diabetes), unless 
not tolerated or contraindicated (2, 3). Metformin 
provides approximately 1–1.5% improvement of HbA1c 
and decreases insulin resistance (4, 5). A feature of the 
metformin therapy is the high variability in glycemic 
response ranging from good clinical response up to 
showing no benefit, and high prevalence of common 
side effects (5–30%) (6, 7, 8). Up to about a third of the 
patients using metformin monotherapy were unable 
to achieve the HbA1c target of 7% (53 mmol/mol) as a 
treatment goal (9).
Metformin is not metabolized in the human body (10); 
its passive diffusion through the cell membranes is very 
limited (11). Its distribution, transportation to the target 
tissues and subsequent excretion from the organism are 
ensured by organic cation transporters (OCTs), multidrug 
and toxin extrusion antiporters (MATEs) and plasma 
membrane monoamine transporter (PMAT) to which 
metformin is a substrate. PMAT (SLC29A4) is expressed 
in human small intestine tissues and is thought to be 
involved in the gastrointestinal absorption of metformin 
(12). Organic cation transporter 1, OCT1 (SLC22A1), is 
expressed mainly in the liver and is a major mediator for the 
metformin uptake into the blood stream from enterocytes 
and the hepatic uptake of metformin (13). Organic cation 
transporter 3, OCT3 (SLC22A3), has a diverse expression 
pattern and is thought to mediate metformin uptake in 
the gastrointestinal tract, muscles, heart and liver; thus, 
it possibly may balance decreased function of OCT1 and 
PMAT (13, 14, 15). Organic cation transporter 2, OCT2 
(SLC22A2), is expressed mainly in the kidney, where 
it transports metformin into the proximal tubule cells 
(16). Finally, multidrug and toxin extrusion antiporters 1 
and 2, MATE1 and MATE2K (SLC47A1, SLC47A2) are 
expressed in brush border of the renal proximal tubule 
and excrete metformin into the urine (17, 18).
Genome-wide complex trait analysis (GCTA) results 
showed that contribution of heritability in glycemic 
response to metformin could be 20–34% and suggested 
that mainly a spectrum of many genetic variants with 
small or moderate effect is involved (19). Results of the 
first genome-wide association study (GWAs) on the long-
term efficiency of metformin support this hypothesis as 
the polymorphism rs11212617, located near the ataxia-
telangiectasia-mutated gene (ATM) and significantly 
associated with metformin response, could explain 
only approximately 2.5% of its variability (20). Several 
case–control pharmacogenetic studies have investigated 
the associations between metformin efficiency and 
pharmacokinetic parameters with SNPs in OCT1, 
OCTN1, OCT2, OCT3, MATE1 and MATE2K coding genes 
(21, 22, 23, 24). Current findings indicate that research 
on metformin efficiency requires complex methods 
involving the identification of genetic variability in 
metformin transporters and pharmacokinetic parameters 
obtained in different mediums (like plasma, erythrocytes 
and urine) simultaneously.
In this study, we aimed to evaluate the clinical 
consequences of systematically selected tagSNPs from 
genomic regions coding for six metformin transporter 
genes with respect to the relatively short-term efficiency, 
where the metformin transporter effects may be the 
most prominent.
Research design and methods
Study group
Study was based on a prospective OPTIMED cohort that 
was launched in 2010 in the framework of the Latvian 
National Research Programme BIOMEDICINE. 28 endo-
crinologists from health care centers and hospitals were 
involved in the recruitment of patients with T2D to main-
tain up to a 3-year long follow-up study. All participants 
were included in the government-funded Genome Data-
base of Latvian Population (LGDB) (27). Inclusion criteria 
were the following: patients with ICD-10 E11 diagnosis 
(fasting blood glucose test result ≥7 mmol/L and/or OGT 
test result ≥11 mmol/L), drug naïve, over 18  years old, 
signed informed consent and lack of pregnancy in women. 
Baseline data on other diagnoses, history of gestational 
diabetes, anthropometric measurements (height, weight, 
waist circumference and blood pressure), intolerance of 
antidiabetic drugs and biochemical analysis were gathered. 
Overall, 313 prospective study participants (OM) were 
recruited in the study on January 2015. 102 patients who 
have received metformin monotherapy for 3 months and 
had corresponding HbA1c measurements (95.5 ± 9.0  days 
after beginning of the therapy) were selected for this study. 
Time before baseline HbA1c measurement and start of the 
therapy was <30 days and was not significantly associated 
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with ΔHbA1c values. OPTIMED project protocol was 
approved by the Central Medical Ethics Committee of 
Latvia (Protocol No. 01-29.1/22).
In Slovakia, the study was conducted in a university 
hospital setting. T2D was diagnosed in patients according 
to the criteria of the American Diabetes Association. The 
Louis Pasteur University Hospital Review Board gave 
ethical approval for this study. All participating subjects 
gave a written consent to be included in the study. 
148 patients of Caucasian origin were recruited from three 
out-patient clinics. Patients with malignancies, another 
endocrine disorders, chronic kidney disease stage 3–5, 
severe liver disease and systemic inflammatory disease 
were excluded. Only drug-naïve patients with HbA1c in 
the range of 6.5–11% (48–97 mmol/mol) were included. 
Baseline HbA1c measurement was performed within 1 week 
before the treatment initiation and second measurement 
was taken after 6  months of metformin monotherapy. 
131 patients were further included in the study as they 
had HbA1c measurements in the corresponding period 
(101.5 ± 20.6 days).
Twenty-five volunteers from Latvia in the 
pharmacokinetic study group ranged between the 
ages of 22 and 37 years and have been evaluated to be 
healthy by a medical doctor. All participants have signed 
informed consent, and the study was approved by the 
Committee of Ethics (Nr.3000610-18L). Study group and 
determination of metformin in blood are described in 
Supplementary methods (see section on supplementary 
data given at the end of this article).
SNP selection and genotyping
We developed a genotyping panel using HaploView 
4.2 (27 genome release) for SNP selection in CEU+TSI 
population. Due to the relatively small expected 
sample size, only variations exceeding minor allele 
frequency (MAF) of 0.05 in Caucasians were included. 
Altogether 192 SNPs and tagSNPs in regions covering 
the 52 genes that are previously reported as influencing 
the efficiency and tolerability of peroral antidiabetic 
therapy were selected. For a particular study, 108 
tagSNPs located in OCT1 (SLC22A1), OCT2 (SLC22A2), 
OCT3 (SLC22A3), MATE1 (SLC47A1), MATE2K 
(SLC47A2) and PMAT (SLC29A4) regions were used. 
DNA samples for genotyping analysis were provided 
by LGDB. Genotyping was performed in all patients 
using GoldenGate Genotyping Assay with VeraCode 
technology (Illumina, San Diego, CA, USA) according 
to the manufacturer’s instructions. One positive control 
sample in each assay plate was used; 19 duplicate 
samples were randomly distributed among the plates. 
Concordance rate of the randomly distributed duplicate 
samples was 99.7%. The GeneCall threshold was set to 
0.25, and samples with call rates lower than 0.9 were 
excluded. The cluster images of signal intensity were 
reviewed manually for all SNPs. 18 from 192 SNPs were 
excluded from the panel after quality control due to 
failed genotyping or weak genotype separation due to 
low fluorescence. Primary data analyses were performed 
using Illumina GenomeStudio software as previously 
reported (26).
In the patient group from Slovakia, OCT2 rs7757336 
and OCT2-OCT3 rs2481030 polymorphisms were 
analyzed by high-resolution melting analysis after real-
time PCR in the presence of LCGreen Plus dye and an 
unlabeled probe on Eco Real-Time PCR System (Illumina). 
Genotypes were identified using Eco Software 4.1. 
Genotyping success rate for all the examined variants was 
100%, and duplicate genotyping concordance was 100% 
(15 samples for each SNP. Where available, 5 samples for 
each genotype were used).
Genetic testing of rs2481030 and rs7757336 in 
pharmacokinetic group was carried out using the 
Applied Biosystems TaqMan SNP (Applied Biosystems). 
Genotyping assay was performed with a modified 
protocol using 4.75 mL TaqMan Genotyping Mix, 0.25 mL 
SNP genotyping assay and 5 mL Millipore H2O on a 7500 
Real-Time PCR system (Applied Biosystems). AutoCaller 
1.1 (Applied Biosystems) software was used to assign 
genotype calls for all samples simultaneously (genotype 
call rate – 100%, concordance rate – 100%).
Statistical analysis
To assess the genotyping quality, statistical analysis was 
performed with the PLINK v1.07 software (http://pngu.
mgh.harvard.edu/purcell/plink/) (27). Two SNPs from 
genotyping panel were excluded due to deviation from 
the Hardy–Weinberg equilibrium P < 0.05 in the controls 
of discovery group. Altogether 102 tagSNPs with a 
genotyping rate of 97.2% in 102 individuals were used in 
further statistical analysis. Statistical power was calculated 
using Quanto software (Natara Software, Naperville, IL, 
USA). Our sample size provided 80% power (at P = 0.05) 
to detect an odds ratios (ORs) from 1.55 to 2.9 depending 
on MAF of SNPs.
Tidwell-Box linearity test, standardized residual 
values, standard errors of mean (s.e.m.) of independent 
variables and Pearson’s r were obtained using SPSS 13.0 
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(Standard version, Chicago, IL, USA) to analyze the 
quality of data and confirm the use of samples in logistic 
and linear regressions performed. The Durbin–Watson 
test, Kolmogorov-Smirnov test and Shapiro–Wilk test, VIF 
and tolerance and standardized residuals were obtained 
using SPSS 13.0 to analyze the quality of data retrieved 
from pharmacokinetic study.
Logistic regression of responders vs non-responders 
(reduction vs no reduction or increase in HbA1c) was 
performed using PLINK 1.07 open software assuming an 
additive mode of inheritance to estimate the association 
of SNPs with non-responsiveness after 3  months of 
metformin monotherapy in the discovery and replication 
groups and using a number of cofactors (age, sex, BMI, 
HbA1c, days of treatment, dose of metformin and creati-
nine clearance) to adjust the analysis for other non-genetic 
factors. Linear regression was performed using PLINK 
1.07 open software to estimate the association of SNPs 
with absolute changes in the obtained pharmacokinetic 
parameters and to correct for covariates (creatinine 
clearance, age, sex and weight).
HaploReg2 was used for exploring annotations of the 
noncoding genome at variants on the haplotype blocks 
and LD information from the 1000 Genomes Project 
(http://www.broadinstitute.org/mammals/haploreg/ 
haploreg.php). IMPUTE version 2 was used for a 
genotype imputation and haplotype phasing with 
combined data from 1000 Genomes Pilot project and 
HapMap 3 (28) (https://mathgen.stats.ox.ac.uk/impute/
impute_v2.html). The 1000 Genomes project browser 
(http://browser.1000genomes.org/index.html), which 
contains the database of phase3 autosomal variants, was 
used to predict the linkage disequilibrium among SNPs 
of interest.
Results
Genetic association study in discovery and  
replication groups
Characteristics of T2D patients included in the study 
are given in Table  1. Baseline HbA1c level was similar 
in both groups; however, the discovery group showed 
significantly better treatment results in a shorter period 
in comparison with the replication group (ΔHbA1c, 
0.9% vs 0.6%). BMI and dose of metformin showed 
significant differences between both the groups. ΔHbA1c 
values were not normally distributed. Thus, Tidwell-Box 
linearity test (P value >0.05), Cook’s distance values <1, 
standardized residual values <2.58 and under maximum 
leverage value confirmed the use of logistic regression 
to ascertain the effects of age, creatinine clearance, 
baseline BMI and HbA1c, sex, length of therapy, dose of 
metformin and 102 SNPs of the 6 metformin transporters 
(OCT1, OCT2, OCT3, MATE1, MATE2-K and PMAT) on 
the likelihood that participants have non-responder 
phenotype (no  changes vs increased HbA1c level) after 
3  months of metformin monotherapy as described 
previously (29).
Data for the associations of all SNPs in the discovery 
group are shown in Supplementary Table  1. In total, 
26 SNPs were nominally (P < 0.05) associated, whereas 
only 3 SNPs remained significantly associated after the 
correction for multiple testing. Table  2 shows 3 SNPs 
that were significantly associated with non-responder 
phenotype after Bonferroni correction, rs2481030, 
rs7757336 and rs3119309. The 1000 Genomes project 
browser (http://browser.1000genomes.org/index.html) 
predicted a high linkage disequilibrium (D′ = 1.0) among 
rs7757336, rs3119309 and rs2481030 in the Caucasians 
Table 1 Characteristics of T2D patient groups from Latvia and Slovakia.
Characteristics Discovery group (n = 102) Replication group (n = 131) P values
Male, n (%) 33 (32.4) 67 (51.1) 0.006
Female, n (%) 69 (67.6) 64 (48.9) 0.006
Mean age ± s.d., years 59.7 ± 10.6 57.4 ± 10.7 0.104
Mean BMI ± s.d., kg/m2, baseline 33.8 ± 4.8 31.4 ± 4.5 <0.0001
Creatinine clearance ± s.d., mL/min 120.1 ± 43.7 105.4 ± 37.1 0.006
Dose of metformin ± s.d., mg/per day 1525.0 ± 533.5 1053.1 ± 486.4 <0.0001
Non-responders to the treatment (decrease of HbA1c, bilance) n, (%) 18 (17.6) 19 (14.5) 0.644
Days between HbA1c measurments ± s.d. 95.5 ± 9.0 101.5 ± 20.6 0.006
HbA1c ± s.d., %, mmol/mol, baseline 7.4 ± 1.5 (57 ± 16.4) 7.6 ± 1.0 (60 ± 10.9) 0.225
HbA1c ± s.d., %, mmol/mol, after treatment, % 6.5 ± 0.6 (48 ± 6.6) 7.0 ± 0.7 (53 ± 7.7) <0.0001
Decrease of HbA1c ± s.d., after treatment, % 0.9 ± 1.3 0.6 ± 0.9 0.039
P  values < 0.05 are marked with bold. P values were assessed using t-test and comparison of proportions.
s.d., standard deviation; BMI, body mass index.
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(CEU) with variable r2 due to differences between MAFs 
(r2 = 0.182–0.657).
The logistic regression model of combined minor 
alleles in the discovery group (count of minor alleles of 
rs2481030 and rs7757336) was statistically significant 
(χ2 (7) = 67.729, P < 0.001). The model explained 80.0% 
(Nagelkerke R2) of the variance in response to metformin, 
and carriers of minor alleles were 12.8 times more likely 
to exhibit non-responder phenotypes than participants 
with reference alleles. Longer time of the therapy, higher 
baseline HbA1c and women gender were associated with a 
lower likelihood of exhibiting non-responder phenotype 
(P < 0.05). Wide confidence intervals of models can be 
explained by small sample size and not as a consequence 
of the high standard errors as s.e.m. values for all logistic 
regression models ≤1.01 and Pearson’s r < 0.8.
SNP imputation of OCT1/OCT2/OCT3 locus was 
performed, but none of the imputed SNPs displayed 
stronger association compared with rs2481030, rs7757336 
and rs3119309.
Two SNPs, rs7757336 and rs2481030, were selected 
for replication from a group of 131 Slovakian T2D patients 
(replication group). In total, 148 Slovakian patients were 
included in a 6-month duration study. Of them, we had 
data on HbA1c from a 3-month visit in 131 patients, 
and these data were analyzed. Minor allele frequencies 
in replication group showed decreased MAF of SNPs 
rs7757336 (0.118, 0.132) and rs2481030 (0.317, 0.397) in 
comparison with the discovery group and HapMap data 
(0.173, 0.398 respectively).
We found no significant associations of SNPs 
rs7757336 and rs2481030 (Omnibus test P value >0.05) 
with non-responder phenotype in group from Slovakia 
after 3  months of metformin monotherapy in a model 
with covariates sex, age, BMI, length of therapy, dose 
(mg/per day), baseline HbA1c and creatinine clearance.
On analysis of a combined group (233 participants), 
logistic regression model is statistically significant 
(χ2 (7) = 76.070, P < 0.001). The model included a number 
of minor alleles of rs2481030 or rs7757336 and age, sex, 
baseline BMI and HbA1c, number of treatment days, 
dose of metformin mg/per day and creatinine clearance 
as covariates. Carriers of minor alleles were 2.00 times 
more likely to exhibit non-responder phenotypes than 
participants with reference alleles (P = 0.002). Higher 
creatinine clearance, higher baseline HbA1c, age and 
women gender were associated with a lower likelihood of 
exhibiting non-responder phenotype (P < 0.05).
Pharmacokinetic study
Association of rs2481030 and rs7757336 with metformin 
pharmacokinetics was analyzed in a group of 25 
participants. Phenotypic and biochemical data of those 
subjects are displayed in Table 3. Nine heterozygotes (AG) 
and 4 homozygotes (GG) of rs2481030 risk allele were 
identified. Eight heterozygotes (AC) of rs7757336 risk 
allele were identified, all being carriers of minor alleles 
of rs2481030 (AG and GG genotypes). Due to the small 
group size, all risk alleles were counted for each participant 
and used as covariates for linear regression analysis. 
For clarity of presentation, 12 participants with 0 risk 
alleles were assigned to the ‘reference’ group, whereas 13 
participants with at least 1 risk allele were assigned to the 
‘risk group’. There are no significant differences in the sex, 
age, weight and creatinine clearance between the groups. 
Table 2 SNPs associated with efficiency of metformin monotherapy in patients from Latvia and Slovakia.
SNP
Genotype number
OR (95% CI)† P† P‡Non-responders Responders 
rs7757336 Discovery group 2/9/7 0/14/70 50.360 (5.998–422.900) 3.06*e−4 0.002
Replication group 0/7/12 1/22/89 1.323 (0.4089–4.282) 0.640 0.826
Combined analysis 2/16/19 1/36/159 4.029 (1.956–8.301) 1.578*e−4 3.137*e−4
rs3119309 Discovery group 1/8/9 0/9/75 26.580 (4.631–152.500) 2.34*e−4 0.001
Replication group NA NA NA NA NA
Combined analysis NA NA NA NA NA
rs2481030 Discovery group 10/7/1 8/38/38 13.700 (3.435–54.670) 2.09*e−4 0.002
Replication group 2/9/8 10/50/52 1.279 (0.563–2.907) 0.557 0.342
Combined analysis 12/16/9 18/88/90 2.933 (1.674–5.137) 1.686*e−4 0.052
Discovery group, Latvia, n = 102 patients, Replication group, Slovakia, n = 131 †OR and P values estimated from logistic regression adjusted for age, sex, 
baseline BMI, number of treatment days, dose of metformin mg/per day, creatinine clearance (Cockroft-Gault equation).
‡P value estimated from logistic regression adjusted for age, sex, baseline BMI, dose of metformin mg/per day, creatinine clearance (Cockroft-Gault 
equation), number of treatment days and baseline HbA1c. P values significant after Bonferroni correction are marked bold.
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The concentration of metformin in plasma was higher in 
the individuals from the reference group compared with 
those in the risk group in 4 sampling points (Fig. 1).
Quality measures for the regression analysis including 
combined number of risk alleles of rs7757336 and 
rs2481030 polymorphisms and covariates – weight, age, 
sex and creatinine clearance (calculated from 24-h urine 
samples and corrected for body surface area) – were as 
follows: R2 = 44.2%, result of the Durbin-Watson test 
=1.83, VIF was 1.06–1.56 and tolerance 0.64–0.95 and 
standardized residuals of linear regression with values 
<±2.17 were normally distributed (P = 0.2) (Table 3).
AUC∞ of metformin plasma was significantly lower 
(P = 0.009) in the risk group (4.62 ± 1.29 µg/h/mL) vs 
reference group (6.30 ± 1.51 µg/h/mL) in linear regression 
analysis. Model including number of risk alleles, age, sex, 
weight and creatinine clearance statistically significantly 
predicted metformin AUC∞ in plasma (sig. F change 
(5, 19) = 3.005, P = 0.036). Weight (P = 0.037) and number 
of minor alleles (P = 0.009), but not age (P = 0.775), sex 
(P = 0.581) and creatinine clearance (P = 0.728) were 
statistically significant variables to the prediction. Cmax 
in plasma was significantly increased in reference group 
(0.84 ± 0.25 vs 0.60 ± 0.18 µg/mL, P = 0.022), and apparent 
clearance (CL/F) was significantly higher in risk group 
(59.64 ± 18.11 L/h vs 42.47 ± 9.50 L/h, P = 0.01). There 
were no significant differences between groups with 
respect to Tmax in plasma, Cmax in erythrocytes, estimated 
half-life and apparent volume of distribution, as well as 
dose of metformin excreted in the urine 24 h after drug 
administration. Tmax in erythrocytes was not analyzed due 
to low variability in study sample.
Discussion
In this study, we show that minor alleles of SNPs 
rs3119309, rs7757336 and rs2481030 located in the 
intergenic region between OCT2 and OCT3 coding genes 
(SLC22A2 and SLC22A3) are significantly associated with 
metformin inefficiency in the 233 newly diagnosed and 
well-described T2D patients. Testing of pharmacokinetic 
effects of these genetic markers was performed in 25 
nondiabetic volunteers from Latvia.























Concentration of metformin in plasma of 25 healthy 
individuals grouped based on the presence of the risk alleles 
after a single-dose oral administration of 500 mg metformin.
Table 3 Characteristics and pharmacokinetics parameters of 25 healthy participants in relation to combined alleles of  
rs2481030 and rs7757336 associated with metformin inefficiency after a single-dose oral administration of 500 mg metformin. 
Data are shown as mean value ± s.d.
Characteristics Study sample
Comparison of groups
Reference (n = 12) Risk group (n = 13) P values
Male n, % 9 (36.00) 3 (25.00) 6 (46.15) 0.473‡
Weight, kg, s.d. 72.68 ± 13.32 71.58 ± 16.59 73.69 ± 10.01 0.701‡
Age, years, s.d. 26.44 ± 3.99 26.17 ± 4.73 26.69 ± 3.35 0.752‡
Creatinine clearance, mL/min/BSA, ±s.d. 121.06 ± 13.72 118.54 ± 16.34 123.38 ± 10.93 0.390‡
AUC∞, µg*h/mL, ±s.d. 5.42 ± 1.62 6.30 ± 1.51 4.62 ± 1.29 0.009
Cmax, µg*mL, plasma, ±s.d. 0.72 ± 0.24 0.84 ± 0.25 0.60 ± 0.18 0.022
Tmax, plasma, h, ±s.d. 2.32 ± 1.25 2.42 ± 1.51 2.23 ± 1.01 NS
Cmax, µg/mL, erythrocytes, ±s.d. 0.15 ± 0.06 0.16 ± 0.07 0.14 ± 0.05 NS
Estimated half-life, h, ±s.d. 4.44 ± 0.62 4.41 ± 0.56 4.46 ± 0.70 NS
CL/F, L/h, ±s.d. 51.40 ± 16.79 42.47 ± 9.50 59.64 ± 18.11 0.010
V/F, L, ±s.d. 333.56 ± 146.18 268.04 ± 59.66 394.03 ± 176.70 NS
Metformin excreted in the urine, % of dose ±s.d. 39.09 ± 12.94 42.19 ± 16.42 36.23 ± 8.31 NS
‡P value derived from t-test. All other P values derived from linear regression with covariates: number of negative alleles, age, sex, weight, 
creatinine clearance (corrected for body surface area (BSA)). NS: linear regression model is not significant (Omnibus test).
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Logistic analysis was performed using robust 
segregation of outcomes in the responder group showing 
decrease in HbA1c vs non-responder group displaying 
no change or even increasing levels of HbA1c 3 months 
after the beginning of metformin monotherapy. The 
main reason to choose this type of outcome is due to our 
intention to perform robust analysis that is better suited 
for the investigation in the small, well-phenotyped group 
(29). A number of studies investigating the efficiency of 
metformin including the only GWAS performed so far 
(20) have used the ΔHbA1c or achievement of treatment 
goal of <6.5 or 7% HbA1c (48–53 mmol/mol) as an 
outcome. However, patients with high baseline HbA1c 
level will usually have larger ΔHbA1c in comparison with 
other participants due to the natural limits. Nevertheless, 
they often will be included in the non-response group if 
treatment goals are set as criteria even if absolute decrease 
of HbA1c is substantial. This may explain the significant 
deviation of ΔHbA1c from the normal distribution in our 
research group. For the same reason, use of treatment 
goals can be misleading in the patients with extreme 
baseline HbA1c values. Patients with high baseline HbA1c 
will have larger HbA1c decrease than patients with HbA1c 
close to normal levels but more often will be classified as 
non-responders (30, 31).
As previously mentioned, GWAS identified an 
association with rs11212617 near ATM, whereas no 
association was found in any loci of known metformin 
transporter genes (20). Our results showing the association 
of SNPs in metformin transporter genes in contrast to 
this GWAS may be explained by relatively short time 
period used to estimate the efficiency of metformin in 
our study. Factors influencing the pharmacokinetics 
(e.g. organic cation transporters) will show their effects 
on efficiency mainly at the beginning of the treatment, 
especially in the case of metformin where gradual 
accumulation of drug has been observed in the organism 
over the time of treatment (21). Short time period is also 
less dependent on factors like diet, physical activities 
and adherence to the drug in comparison with the long-
term treatment when metformin secondary failure due 
to decreasing body functions interferes. In addition, one 
should take into account the fact that initial metformin 
therapy is subject to change after the first 3  months 
of the therapy in cases where it failed to display the 
decrease of HbA1c. A study investigating metformin 
therapy outcomes assessed initial nonadherence to be 
17% in participants starting metformin therapy. One-
third attempted another pharmacotherapy within 
6 months, and side effects were found to be one of the 
major limiting factors (32, 33, 34). Thus, the patients 
whose treatment inefficiency is caused by the defect in 
metformin transport may become eliminated from the 
studies involving longer observation times.
Our failure to replicate the association of identified 
SNPs in the replication group of 131 T2D participants 
from Slovakia may be explained by the differences in the 
phenotypical and genotypical characteristics of the groups. 
Among the phenotypical differences, significantly lower 
BMI, lower dose of metformin used and subsequently a 
lower reduction in HbA1c were observed in the replication 
group in comparison with those in the discovery group. 
SNPs rs7757336 and rs2481030, age, sex, BMI, HbA1c, 
metformin dose and creatinine clearance were not 
associated with non-responder phenotype, indicating 
a strong influence of other genetic or environmental 
factors like diet, physical activities and adherence to 
the metformin. MAF of the investigated SNPs in the 
replication group was lower compared with that found 
in the discovery group, and linkage disequilibrium 
differed (r2 = 0.255 vs 0.194) indicating significant genetic 
differences between populations. However, it should be 
noted that the effect direction in the Slovakian group was 
similar to that observed in the Latvian group (OR 1.32, 
although non-significant). The results from combined 
analysis probably correspond better with the real-life effect 
size of the polymorphism with response to metformin, 
which could have been inflated in the original Latvian 
study as a result of statistical phenomenon called the 
‘winner’s curse’. The combined analysis was made across 
the wider spectrum of metformin dosage, which was also 
taken into account as one of the covariates.
In line with the results of the pharmacogenetic 
study, in the pharmacokinetic study, the minor alleles 
of rs775336 and rs2481030 were also consistently 
associated with lower concentration of metformin and 
AUC∞ of the plasma in a small independent group of 
25 healthy nondiabetic volunteers. Due to the limited 
number of participants, it is necessary to confirm these 
findings in studies with a larger number of subjects. 
However, if these findings hold true, this will support 
the influence of OCTs in pharmacokinetics of metformin 
and importance of short-term study design in cases where 
factors influencing bioavailability are investigated. No 
significant differences were found in observed Cmax and 
Tmax in erythrocytes between controls and carriers of risk 
alleles indicating that observed changes of metformin 
pharmacokinetics cannot be explained by exposure time 
to metformin. When other pharmacokinetic measures 
were analyzed, we found that oral clearance (CL/F) is 
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higher in the subjects with at least one inefficient allele, 
whereas apparent volume of distribution (V/F), half-life 
and total dose of metformin excreted in the first 24 h 
after administration were not different. It should be 
noted however that calculation of renal clearance and 
apparent volume of distribution were done assuming that 
there is no difference in the bioavailability of 500 mg of 
metformin taken orally. This assumption may not be true 
as a number of factors including the genetic variation 
in transporter genes may alter the bioavailability. The 
calculated CL/F and V/F values are strongly related to 
AUC∞ measurement, and their difference among groups 
should be interpreted with caution.
Variation in the bioavailability and volume of 
distribution is considered a major source of variation in 
the pharmacokinetics of metformin as it does not undergo 
metabolization in the human body and slow absorption 
is thought to be the rate-limiting factor in metformin 
disposition (10). It is not clear what proportion of metformin 
is sequestered in the enterocytes due to the effects of inward 
net flow and OCT related mechanism vs its paracellular route 
in human small intestine. If latter is true, the uptake and 
excretion remain the major factors influencing metformin 
plasma levels. Lower metformin level in plasma may 
indicate lower metformin uptake in the gastrointestinal tract 
by altered OCT3 transporter or can be explained by OCT2 
variant that eliminates the drug more quickly.
Polymorphisms investigated in this study are 
noncoding and could be in linkage disequilibrium with 
causal SNPs within coding/regulatory regions of SLC22A2, 
SLC22A3 or even SLC22A1 resulting in altered transport 
activity or expression level in target tissues. In large GWAS, 
minor allele A of SNP rs3127573 (MAF 0.13) located near 
SLC22A2 (r2 =0.96 with SNP rs3119309 investigated in our 
study) was identified to be associated with higher serum 
creatinine and lower estimated GFR (35). However, it is 
not clear how variants in OCT2 or its regulatory regions 
could be a basis for increased creatinine levels and 
decreased metformin levels simultaneously.
On the other hand, these can be explained by 
altered transport activity of creatinine and metformin 
transporter OCT3 (SLC22A3), which is expressed in the 
liver, small intestine and muscle tissue. Indeed, in the 
experiments with OCT2 and OCT3 expressing HEK293 
cells (36), increased creatinine uptake in comparison 
with cells transfected with the null vector was identified, 
whereas such uptake was not observed in case of OCT1. 
Polymorphisms rs2292334, rs2048327, rs1810126 and 
rs3088442 were associated with reduced OCT3 mRNA 
levels, whereas a common variant of rs555754 was 
associated with a greater transcription rate and higher 
expression levels of OCT3 in the liver (37). While none of 
the above-mentioned SNPs altering the OCT3 transporter 
efficiency were in strong linkage disequilibrium 
with SNPs investigated in our study, rs2481030 and 
rs2481031 (LD with r2 =0.99) (http://www.broadinstitute.
org/mammals/haploreg/haploreg_v2.php). Possibly, 
rs2481030 could be a marker of reduced uptake 
OCT3 variant or lower transporter expression level 
and subsequently characterized by slower metformin 
absorption from gastrointestinal tract and decreased 
uptake in the liver, muscle, heart and adipose tissues.
Major limitations of our study are the relatively 
small sample size, possible effects of co-medications 
and adherence. Variable co-medications in antidiabetic 
therapy are very common, however, the stratification 
based on this variable or analysis of patients without 
concomitant diseases would result in significant selection 
bias and insignificant sample size. Particular functional 
variants, for example, OCT1 risk alleles of metformin 
intolerance were not included in this study (38) mainly 
because of low allele frequency that would result in 
very low statistical power due to small sample size. 
Our findings should be evaluated in larger groups of 
participants. Further investigation should be conducted 
to confirm whether rs7757336, rs3119309 and rs2481030 
are valid markers of metformin inefficiency and if they 
can be useful in the prediction of treatment response to 
metformin in the T2D patients.
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